In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the

CtHtrA inhibitor JO146
Vanissa A. Chlamydia (C.) trachomatis is an obligate intracellular bacterial pathogen and is a commonly reported bacterial sexually transmitted pathogen worldwide. In the United States, over 1.4 million cases of C. trachomatis infection were reported in 2012, the highest number of cases ever reported to CDC for any condition [1] .
Currently, the recommended first line of treatment for uncomplicated genital C.
trachomatis infections is a single 1.0 g oral dose of the macrolide antibiotic azithromycin [2] .
However, a number of recently published studies challenge the efficacy of azithromycin therapy for chlamydial infections [3] [4] [5] [6] . Batteiger and co-workers [6] conducted a cohort study among adolescent women and used a classification algorithm to characterize treatment outcomes among the study subjects after directly observed azithromycin treatment. Among women with paired episodes of chlamydial infections, 8% were probable treatment failures.
A partner treatment study conducted by Golden and co-workers [7] reported that 8% (22 of 289 originally treated for Chlamydia) of cases treated reported no sexual intercourse after treatment and were classified as treatment failures. These studies suggest the possible future need for improved anti-chlamydial therapies.
Our group identified a serine protease inhibitor, JO146, against C. trachomatis High Temperature Requirement A (CtHtrA) [8] [9] [10] [11] . JO146 was found to be lethal to C. trachomatis D when added at the mid-replicative stage of the chlamydial developmental cycle [8] . The addition of JO146 was lethal during reversion or recovery from penicillin persistence and during heat stress [12] .
Laboratory strains of C. trachomatis that are commonly used for biological experiments may not reflect the isolates currently infecting men and women [13] . Differences in genome dynamics, and virulence attributes and infectivity [14] [15] [16] and serially diluted onto McCoy B cultures. At 30 h PI, cultures were fixed and stained using immunocytochemistry for host nucleus and chlamydial inclusions, and examined by microscopy to enumerate inclusion forming units [18] .
Confocal microscopy
McCoy B cells infected with C. trachomatis cultured on coverslips were used for confocal microscopy. At nominated time points the cells were fixed and immunocytochemistry conducted as previously described [12] . Confocal images were obtained using an Olympus FV1200 confocal laser scanning microscope (FluoView ® FV1200, Olympus Corporation, Japan). Sizes of 30 independent inclusions for each treatment and time point were measured manually through the use of NIS-Elements Basic Research 3.2 software.
Western blot
Cultures of T25 flasks of McCoy B cells infected with C. trachomatis were harvested for western blot analysis of the Major Outer Membrane protein (MOMP) and host β-actin after JO146 treatment at 16 h PI and harvested at 24 h PI. Western blots were conducted as previously described [22] .
Statistical analysis
Statistical analysis was performed using PRISM (GraphPad Software Inc., V7.0).
Statistical significance was defined as p < 0.05. Statistical tests used and number of samples are indicated with each figure.
Results
HtrA inhibition using JO146 during McCoy B culture of chlamydial isolates prevents chlamydial inclusion vacuole size development
Our previous work using HEp-2 cells on C. trachomatis D (UW-3/Cx) a long term passaged isolate (referred to here as CtD) demonstrated that the inclusions decreased in size and were lost from the host cells [18] . Therefore, here we examined the morphology of the 
JO146 treatment during mid-replicative phase of chlamydial development in McCoy B cells resulted in a loss of infectious progeny for clinical isolates
The effect of 16 h PI JO146 treatment on the development of infectious progeny was tested. No infectious progeny (44 h PI) were observed for all clinical isolates treated with 50 and 100 µM JO146 except for isolate 1-017(13) (Fig. 2) . For isolate 1-017(13) treatment with 50 µM JO146 resulted in approximately 1 log less infectious yield compared to DMSO and media controls (p<0.001) and 100 µM resulted in a complete loss of infectious progeny as consistent with the other clinical isolates. Treatment of the type strain C. trachomatis D with 50 and 100 µM JO146 both resulted in ~1.5 log less infectious progeny compared to that observed in the DMSO control (p < 0.0001) (Fig. 2) .
The reduction in infectious progeny and reduced inclusion sizes (Fig. 1) should correlate with a decrease in the detection of chlamydial protein. A western blot to detect levels of MOMP 8 h after JO146 treatment, showed a reduction of MOMP levels compared to matched DMSO controls for most of the isolates (Supplementary Fig.S2 ).
JO146 requires long treatment times to be effective against C. trachomatis in McCoy B cultures
In order to determine if JO146 activity against chlamydial clinical isolates is effective with a short duration of treatment, we removed JO146 from the cultures 8 h after addition. This resulted in recovery of infectious progeny at 44 and 68 h PI in all clinical isolates ( Fig. 3 ) in contrast to complete loss of progeny when the compound was left in the cultures (Fig. 2) . In C. trachomatis clinical isolates 1-028(1) and 1-019(1), there were fewer infectious EBs in cells treated with 100 µM JO146 compared to the cells treated with 0 µM JO146 (media only) and DMSO controls either at 44 or 68 h PI (Fig. 3) . A non-significant increase was observed in the number of infectious progeny at 68 h PI compared to 44 h PI with 100 M JO146 for isolates 1-017(13), 1-079(1), 1-048(1) and 1-020(1) (Fig. 3) . Overall, an 8 h JO146 treatment of the cultures resulted in a minor loss of infectious progeny compared to when the compound was left in the cultures until the end of the developmental cycle ( Fig. 2) , suggesting that in McCoy B cultures there is a need for longer treatment duration for efficacy.
Discussion
Here, we set out to determine if these previous observations of a critical function for CtHtrA inhibitor JO146 resulted in diminishing chlamydial inclusion size, eventual loss of the inclusions, and loss of infectious progeny without being toxic to the host cells [8] . CtHtrA was found to be essential for the reversion and recovery to viability from penicillin persistence and during heat stress [12] . The critical role that CtHtrA plays during the replicative phase of the chlamydial developmental cycle was also demonstrated to be conserved among other C. trachomatis strains and other Chlamydia species such as C.
pecorum, C. suis, and C. caviae [22] . The exact role of CtHtrA for the replicative phase remains unknown, and it is potentially and indirect effect of CtHtrA, and that one or more specific extra-cytoplasmic protein substrates that rely on CtHtrA for assembly is the required factor for replicative phase. [23, 24] .
In the present study the chlamydial inclusions were not completely lost from the host cells after JO146 treatment (in contrast to complete inclusion loss previously observed in
HEp-2 cells), however these inclusions did not contain infectious progeny (Fig 1. and Fig 2. ) [18] . Infectious progeny (with comparatively minor loss compared to controls) were observed for all strains tested when the cultures were treated with JO146 for 8 h at the replicative phase host process than that of these fibroblasts is able to target the vacuoles. Nonetheless it is clear that CtHtrA is a valid possible target should future therapeutics need to be developed against Chlamydia, based on the effectiveness against these clinical isolates.
The subtle differences in JO146 efficacy observed between the isolates and the type strain C. trachomatis D is not able to be explained by differences in CtHtrA amino acid sequence. The CtHtrA sequence is highly conserved with at most 4 amino acids different in the 647 amino acid sequence across the published C. trachomatis genomes to date. The C.
trachomatis genomes cluster into three predominant clades (LGV, T1, T2) [25] , the CtHtrA sequences that we have determined so far from our clinical isolates are consistent with the T2
clade (1-017(13), 1-017(1), 1-028(1), 1-048(1) (sequences will be published elsewhere). The amino acid variation is not near the residues that form active site where JO146 binds to the protein and is not likely to explain the variation. However, other differences that might impact on growth kinetics of pharmacokinetics of the drug on the chlamydial strains, as well as differences on the host cell factors do require further investigation in the future.
Conclusions
This preliminary study supports that JO146 is effective against recent clinical isolates of C. trachomatis. The data indicates that in vitro application of an inhibitor compound that targets CtHtrA during the replicative phase of recent clinical isolates of C. trachomatis prevents development of infectious progeny. CtHtrA therefore, could be a potential target for future drug development for C. trachomatis and we suggest that CtHtrA inhibition and JO146
should be further investigated for improved drug development.
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